## Mohsen Kerkeni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/284473/publications.pdf

Version: 2024-02-01

		687363	888059
19	542	13	17
papers	citations	h-index	g-index
19	19	19	738
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Weak Association between Skin Autofluorescence Levels and Prediabetes with an ILERVAS Cross-Sectional Study. Nutrients, 2022, 14, 1102.	4.1	O
2	RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?. Medical Hypotheses, 2020, 144, 109950.	1.5	27
3	Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project. Journal of Atherosclerosis and Thrombosis, 2019, 26, 879-889.	2.0	9
4	Advanced Glycation End Products Levels and Carotid Intima Media Thickness in Patients With Rheumatoid Arthritis. Journal of Biology and Life Science, 2019, 10, 58.	0.2	0
5	Increased serum concentrations of N $<$ sup $>$ É $<$ /sup $>$ -carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis. Annals of Clinical Biochemistry, 2018, 55, 430-436.	1.6	15
6	Methylglyoxal: A Relevant Marker of Disease Activity in Patients with Rheumatoid Arthritis. Disease Markers, 2018, 2018, 1-6.	1.3	17
7	Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect. Disease Markers, 2016, 2016, 1-8.	1.3	39
8	Increased serum homocitrulline concentrations are associated with the severity of coronary artery disease. Clinical Chemistry and Laboratory Medicine, 2015, 53, 103-10.	2.3	31
9	Increased serum concentrations of pentosidine are related to presence and severity of coronary artery disease. Thrombosis Research, 2014, 134, 633-638.	1.7	37
10	Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes and Vascular Disease Research, 2013, 10, 239-245.	2.0	64
11	Apolipoprotein A-I, apolipoprotein B, high-sensitivity C-reactive protein and severity of coronary artery disease in tunisian population. Cardiovascular Pathology, 2012, 21, 455-460.	1.6	5
12	Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvascular Research, 2012, 84, 378-383.	2.5	41
13	Hyperhomocysteinemia, paraoxonase concentration and cardiovascular complications in Tunisian patients with nondiabetic renal disease. Clinical Biochemistry, 2009, 42, 777-782.	1.9	11
14	Endothelial nitric oxide synthetase, methylenetetrahydrofolate reductase polymorphisms, and cardiovascular complications in Tunisian patients with nondiabetic renal disease. Clinical Biochemistry, 2009, 42, 958-964.	1.9	14
15	Hyperhomocysteinaemia and parameters of antioxidative defence in Tunisian patients with coronary heart disease. Annals of Clinical Biochemistry, 2008, 45, 193-198.	1.6	19
16	Comparative Study on in Vitro Effects of Homocysteine Thiolactone and Homocysteine on HUVEC Cells: Evidence for a Stronger Proapoptotic and Proinflammative Homocysteine Thiolactone. Molecular and Cellular Biochemistry, 2006, 291, 119-126.	3.1	58
17	Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clinical Biochemistry, 2006, 39, 821-825.	1.9	58
18	Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Annals of Clinical Biochemistry, 2006, 43, 200-206.	1.6	47

## Mohsen Kerkeni

#	Article	IF	CITATIONS
19	Hyperhomocysteinemia, Endothelial Nitric Oxide Synthase Polymorphism, and Risk of Coronary Artery Disease. Clinical Chemistry, 2006, 52, 53-58.	3.2	50